Clinical Trial Update: TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TR-701 (tidarubicin? actually TR-701 is dalbavancin-like? Not sure) for acute bacterial skin and skin structure infections versus linezo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infections

Drugs mentioned

• Linezolid (Linezolid)
• TR-701

Snippet

Sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Skin and Subcutaneous Tissue Bacterial Infections | Phase 3 | Status: COMPLETED | Results posted: 2014-09-03